---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-000082"
form_type: "8-K"
ticker: "CMPX"
cik: "0001738021"
company_name: "Compass Therapeutics, Inc."
filed_at: "2024-01-05T23:59:59+00:00"
generated_at: "2026-06-07T03:13:23.932177+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Compass Therapeutics: CEO change to Bisker-Leib, CTX-471 CR in SCLC, $152M cash

## Summary
- CEO succession: Vered Bisker-Leib appointed CEO effective Jan 9, 2024; Thomas Schuetz becomes President of R&D and Vice Chair.
- Year-end 2023 cash & securities ~$152M, providing runway into mid-2026.
- CTX-471: SCLC patient partial response converted to complete response; new PR in melanoma yields 27% ORR (3/11).
- CTX-009: COMPANION-003 top-line data expected mid-2024; COMPANION-002 top-line data in H2 2024.
- CTX-8371 IND accepted; first patient dosing expected in Q1 2024.

## SEC filing metadata
- accession: 0001171843-24-000082
- form_type: 8-K
- ticker: CMPX
- cik: 0001738021
- company_name: Compass Therapeutics, Inc.
- filed_at: 2024-01-05T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1738021/000117184324000082/0001171843-24-000082-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1738021/000117184324000082/f8k_010524.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-000082
- JSON: https://secwatch.observer/filing/0001171843-24-000082.json
- Plain text: https://secwatch.observer/filing/0001171843-24-000082.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.